Martin E Dowty

List of Publications by Citations

42 papers	2,207 citations	22 h-index	46 g-index
46 ext. papers	2,609 ext. citations	4.8 avg, IF	4.05 L-index

#	Paper	IF	Citations
42	Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). *Journal of Immunology*, **2011**, 186, 4234-43	5.3	466
41	Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. *Journal of Inflammation*, **2010**, 7, 41	6.7	327
40	The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. *Clinical and Experimental Rheumatology*, **2016**, 34, 318-28	2.2	155
39	The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. *Drug Metabolism and Disposition*, **2014**, 42, 759-73	4	142
38	Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. *Journal of Medicinal Chemistry*, **2000**, 43, 369-80	8.3	87
37	Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. *ACS Chemical Biology*, **2016**, 11, 3442-3451	4.9	85
36	Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 348, 165-73	4.7	79
35	Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. *Journal of Medicinal Chemistry*, **2017**, 60, 1971-1993	8.3	77
34	Approach for extrapolating in vitro metabolism data to refine bioconcentration factor estimates. *Chemosphere*, **2008**, 70, 1804-17	8.4	71
33	Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. *Journal of Medicinal Chemistry*, **2000**, 43, 4948-63	8.3	68
32	Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. *Journal of Medicinal Chemistry*, **2018**, 61, 1130-1152	8.3	57
31	A holistic strategy for characterizing the safety of metabolites through drug discovery and development. *Chemical Research in Toxicology*, **2009**, 22, 1653-62	4	57
30	Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). *Journal of Medicinal Chemistry*, **2018**, 61, 8597-8612	8.3	54
29	Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold. *Journal of Medicinal Chemistry*, **1999**, 42, 5426-36	8.3	49
28	Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. *MAbs*, **2016**, 8, 1064-78	6.6	47
27	The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. *Journal of Clinical Pharmacology*, **2018**, 58, 434-447	2.9	41
26	Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. *Pharmacology Research and Perspectives*, **2019**, 7, e00537	3.1	41

25	Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data. *British Journal of Clinical Pharmacology*, **2012**, 74, 109-15	3.8	29
24	The next generation of MMP inhibitors. Design and synthesis. *Annals of the New York Academy of Sciences*, **1999**, 878, 40-60	6.5	29
23	Improved prediction of in vivo peroral absorption from in vitro intestinal permeability using an internal standard to control for intra- and inter-rat variability. *Pharmaceutical Research*, **1997**, 14, 1792-7	4.5	27
22	Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 10665-10699	8.3	23
21	Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms. *Drug Metabolism and Disposition*, **2017**, 45, 1-7	4	22
20	How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential. *Drug Metabolism and Disposition*, **2011**, 39, 1779-83	4	22
19	Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS). *ACS Medicinal Chemistry Letters*, **2010**, 1, 59-63	4.3	19
18	Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. *Journal of Medicinal Chemistry*, **2020**, 63, 13561-13577	8.3	19
17	Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents. *Journal of Medicinal Chemistry*, **2008**, 51, 6055-66	8.3	18
16	Small-molecule melanin-concentrating hormone-1 receptor antagonists require brain penetration for inhibition of food intake and reduction in body weight. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 324, 206-13	4.7	14
15	Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic approach. *Journal of Medicinal Chemistry*, **2006**, 49, 4745-61	8.3	10
14	The efficacy and cardiac evaluation of aminomethyl tetrahydronaphthalene ketopiperazines: a novel class of potent MCH-R1 antagonists. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 2092-105	3.4	8
13	Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists--Increasing selectivity over hERG. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 819-22	2.9	8
12	Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2. *Clinical Pharmacology in Drug Development*, **2014**, 3, 499-507	2.3	7
11	Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. *Journal of Clinical Pharmacology*, **2021**, 61, 1311-1323	2.9	7
10	Novel pyrazolopiperazinone- and pyrrolopiperazinone-based MCH-R1 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 657-61	2.9	6
9	Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study. *Clinical and Translational Science*, **2021**, 14, 671-682	4.9	6
8	LC-MS/MS assay for N-methylnicotinamide in humans, an endogenous probe for renal transporters. *Bioanalysis*, **2018**, 10, 673-689	2.1	5

7	Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences. *Scientific Reports*, **2020**, 10, 8974	4.9	4
6	Drug design structural alert: formation of trifluoroacetaldehyde through N-dealkylation is linked to testicular lesions in rat. *International Journal of Toxicology*, **2011**, 30, 546-50	2.4	4
5	Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib. *Journal of Clinical Pharmacology*, **2020**, 60, 1617-1628	2.9	3
4	Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1. *Bioorganic and Medicinal Chemistry*, **2020**, 28, 115481	3.4	3
3	ADME **2010**, 145-200		3
2	Animal Models for Evaluation of Drug-Drug Interaction Potential of Biotherapeutics. *Current Drug Metabolism*, **2012**, 13, 947-950	3.5	2
1	Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.. *European Journal of Drug Metabolism and Pharmacokinetics*, **2022**, 1	2.7	1